Clinical Trial Update: Enoxaparin for Primary Thromboprophylaxis in Ambulatory Patients With COVID-19 [Phase 3]

View source ↗

Summary

Phase 3 trial of enoxaparin for primary thromboprophylaxis in ambulatory COVID-19 patients was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Deep Vein Thrombosis
• Pulmonary Embolism

Drugs mentioned

• Enoxaparin (enoxaparin sodium)

Snippet

Sponsor: University of Zurich | Conditions: COVID-19, Pulmonary Embolism, Deep Vein Thrombosis | Phase 3 | Status: TERMINATED